Published in Science on September 24, 2015
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A (2016) 1.08
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics (2016) 0.93
On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry. J Am Chem Soc (2016) 0.86
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Harnessing the immune system to improve cancer therapy. Ann Transl Med (2016) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol (2016) 0.81
Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol (2016) 0.81
Design of chimeric antigen receptors with integrated controllable transient functions. Sci Rep (2016) 0.81
The quest for spatio-temporal control of CAR T cells. Cell Res (2015) 0.80
Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res (2016) 0.79
Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends Biotechnol (2016) 0.78
New development in CAR-T cell therapy. J Hematol Oncol (2017) 0.78
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol (2017) 0.77
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol (2016) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Chimeric antigen receptor-modified T cells strike back. Int Immunol (2016) 0.76
Microfluidic models for adoptive cell-mediated cancer immunotherapies. Drug Discov Today (2016) 0.76
An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep (2017) 0.75
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment. Front Immunol (2017) 0.75
Plant Chemical Genetics: From Phenotype-Based Screens to Synthetic Biology. Plant Physiol (2017) 0.75
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol (2016) 0.75
Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev (2016) 0.75
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer (2017) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Rewiring MAP kinases in Saccharomyces cerevisiae to regulate novel targets through ubiquitination. Elife (2016) 0.75
Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response. Trends Mol Med (2016) 0.75
Immunotherapy: Remote control CARs. Nat Rev Drug Discov (2015) 0.75
Immunotherapy: Remote control CARs. Nat Rev Immunol (2015) 0.75
Modular engineering of cellular signaling proteins and networks. Curr Opin Struct Biol (2016) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. J Cell Physiol (2016) 0.75
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther (2017) 0.75
Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget (2017) 0.75
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol (2017) 0.75
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. J Cancer (2017) 0.75
Imaging intracellular fluorescent proteins at nanometer resolution. Science (2006) 38.97
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Signal transduction by lymphocyte antigen receptors. Cell (1994) 10.63
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
High-density mapping of single-molecule trajectories with photoactivated localization microscopy. Nat Methods (2008) 7.87
Single-molecule microscopy reveals plasma membrane microdomains created by protein-protein networks that exclude or trap signaling molecules in T cells. Cell (2005) 7.27
A genetically encoded photoactivatable Rac controls the motility of living cells. Nature (2009) 7.25
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature (2009) 6.74
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (1996) 5.92
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell (2012) 5.15
Rapid blue-light-mediated induction of protein interactions in living cells. Nat Methods (2010) 4.70
An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 4.56
Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science (2000) 4.09
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol (2003) 3.88
T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol (2004) 3.85
Gibberellin-induced DELLA recognition by the gibberellin receptor GID1. Nature (2008) 3.29
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell (1999) 2.25
Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med (1993) 2.17
Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci U S A (2010) 2.01
Unnatural ligands for engineered proteins: new tools for chemical genetics. Annu Rev Biophys Biomol Struct (2000) 1.99
Neural stem cell engraftment and myelination in the human brain. Sci Transl Med (2012) 1.96
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83
Rewiring cell signaling: the logic and plasticity of eukaryotic protein circuitry. Curr Opin Struct Biol (2004) 1.83
Light-based feedback for controlling intracellular signaling dynamics. Nat Methods (2011) 1.79
Isolation of mouse peritoneal cavity cells. J Vis Exp (2010) 1.79
Conditional control of protein function. Chem Biol (2006) 1.78
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol (2013) 1.74
Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen. Proc Natl Acad Sci U S A (1997) 1.66
Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol (2006) 1.65
Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol (1996) 1.51
Cell therapy industry: billion dollar global business with unlimited potential. Regen Med (2011) 1.29
Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood (1994) 1.26
Counting molecules in single organelles with superresolution microscopy allows tracking of the endosome maturation trajectory. Proc Natl Acad Sci U S A (2013) 1.26
The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J Cell Biol (2003) 1.25
Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. EMBO J (1997) 1.23
Rapid and orthogonal logic gating with a gibberellin-induced dimerization system. Nat Chem Biol (2012) 1.20
Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B. Biochem Biophys Res Commun (1998) 1.01
The use of light for engineered control and reprogramming of cellular functions. Curr Opin Biotechnol (2011) 0.96
Synthetic mammalian gene circuits for biomedical applications. Curr Opin Chem Biol (2013) 0.95
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A (2014) 0.92
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med (2015) 0.84